Companies in #COPD

Biotech developing disease-controlling treatments for COPD and other neutrophil-driven inflammatory respiratory diseases. Lead candidate EXPD-101 is an oral, once-daily DPP1 inhibitor advancing into a global Phase 2 COPD trial. Backed by Sanofi.

Theravance Biopharma is a specialty biopharmaceutical company focused on respiratory diseases, commercializing YUPELRI (revefenacin) for COPD through a Viatris partnership, with a research pipeline targeting lung disease.